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We identified ZNF683/HOBIT as the most highly upregulated transcription factor gene 
during ex vivo differentiation of human CD34+ cord blood progenitor cells to CD56+ 
natural killer (NK) cells. ZNF683/HOBIT mRNA was preferentially expressed in NK cells 
compared to other human peripheral blood lymphocytes and monocytes. During ex vivo 
differentiation, ZNF683/HOBIT mRNA started to increase shortly after addition of IL-15 
and further accumulated in parallel to the generation of CD56+ NK cells. shRNA-mediated 
knockdown of ZNF683/HOBIT resulted in a substantial reduction of CD56−CD14− NK-cell 
progenitors and the following generation of CD56+ NK cells was largely abrogated. The 
few CD56+ NK cells, which escaped the developmental inhibition in the ZNF683/HOBIT 
knockdown cultures, displayed normal levels of NKG2A and KIR receptors. Functional 
analyses of these cells showed no differences in degranulation capacity from control cul-
tures. However, the proportion of IFN-γ-producing cells appeared to be increased upon 
ZNF683/HOBIT knockdown. These results indicate a key role of ZNF683/HOBIT for the 
differentiation of the human NK-cell lineage and further suggest a potential negative 
control on IFN-γ production in more mature human NK cells.
Keywords: ZnF683/hOBiT, natural killer cells, cD56, ex vivo differentiation, nK-cell development
inTrODUcTiOn
Natural killer (NK) cells are the third largest group of lymphocytes in peripheral blood and an 
important component of the first line of immune defense. They act against a wide spectrum of 
virally infected and neoplastic cells by direct killing of these cells or production of cytokines, 
such as IFN-γ. As components of the innate part of the immune system, they display immediate 
reactivity and do not require prior sensitization (1, 2). This traditional characterization of NK cells 
has been expanded over the recent years as they have been described to be able to incorporate 
features previously thought to be restricted to the adaptive immune system, such as interaction with 
dendritic cells and immunological memory (3–5). In contrast to the adaptive T and B lymphocytes, 
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NK cells lack somatically recombined and clonally distributed 
antigen receptors, and their activity is controlled by a varied 
repertoire of germline-encoded inhibitory and activating recep-
tors (6). Recently, additional tissue-resident subsets of innate 
lymphoid cells (ILCs), distinct from NK cells, became apparent 
and significantly expanded the complexity of innate lymphoid 
lineages. Whereas conventional NK  cells resemble cytotoxic 
T lymphocytes in many aspects, ILCs 1–3 rather mirror T helper- 
like cells (7).
Based on currently available data, the relationship between the 
different innate and adaptive lymphoid lineages is reflected by 
their initial common differentiation from the hematopoietic stem 
cell (HSC) and in similarities of their transcriptional networks. 
According to the current hypothesis, the HSC develops through a 
multipotent progenitor to a common lymphoid progenitor (CLP) 
(8). This CLP can further differentiate into adaptive lymphocytes 
under the control of E-proteins, whereas the development of 
innate lymphocytes requires antagonism of E-proteins and likely 
proceeds through a common innate lymphoid progenitor (9, 10). 
The following pre-NK progenitor (NKP) stage restricts the 
differentiating cells to the NK lineage and develops into NKP 
and subsequently into immature NK (iNK) cells. The final step 
involves maturation from the iNK  cells to mature NK (mNK) 
cells, both stages expressing the NK marker CD56 (11, 12).
Substantial data have been obtained to identify key transcrip-
tion factors essential for the differentiation of adaptive and innate 
lymphocytes. A common theme appears to be the mutual inhibition 
of factors determining different lineages. For example, EBF strongly 
inhibits ID2 expression, thereby allowing E2A to function during 
B-cell development. In addition, EBF and PAX5 support B-cell dif-
ferentiation by repressing additional critical regulators of T-cell and 
ILC differentiation, such as NOTCH1, GATA-3, and TCF-1 (8, 9). 
Conversely, all ILCs including NK  cells are dependent for their 
diff erentiation on ID2 that heterodimerizes with E proteins and 
neutralizes their activity (10). Subsequently, a complex network 
of transcription factors guides the cells through the distinct steps 
of NK-cell differentiation (13). The most important transcription 
factors for the early stages of murine NK-cell development include 
STAT5, two ETS family members (PU.1 and ETS-1), and NFIL3 
(also known as E4BP4) (14–17). The maturation stage from iNK 
to mNK cells and NK cells’ function are coordinated by BLIMP-1, 
T-BET, EOMES, and MEF among others (18–20). Compared to the 
data obtained from the murine system, experimental evidence on 
transcription factors governing human NK-cell development is far 
less available. This has been partially caused by the lack of an easy 
and robust system to mimic human NK-cell differentiation from 
HSC ex vivo. Of the few transcription factors described so far, TOX1 
and 2 are important in the early stages, T-BET and BLIMP-1 both 
play critical roles in the later phases and effector functions of human 
NK cells (21–24). From the currently available data, it appears that 
the precise function and sequential order of transcription factors 
directing NK-cell development may to some extent differ between 
mice and humans.
Due to their important role in immunosurveillance, NK cells 
and their modulation are currently being explored as a therapeu-
tic approach in a wide variety of cancers, autoimmune diseases, 
allergies, and transplantation (1, 25). These attempts have led 
to the development of methods for the specific modulation of 
endogenous NK cells as well as for ex vivo amplification of NK cells 
from patients or allogeneic donors for NK cell-infusion therapies. 
The obtained results show clear benefits of NK cell-based thera-
pies, in comparison to T  lymphocyte-based, including a good 
tolerance of allogeneic NK cells by the patients and the lack of a 
graft-versus-host disease (1, 25). Different strategies are exploited 
to obtain a sufficient number of NK cells for infusion therapies, 
including cytokine- and/or feeder cell-mediated expansion of 
peripheral blood NK cells as well as ex vivo differentiation from 
cord or peripheral blood-derived HSC (26, 27). In this regard, 
we have previously analyzed a feeder cell-free ex vivo system to 
generate large-scale therapeutic NK cells from cord blood stem 
cells that faithfully reproduces different steps of human NK-cell 
differentiation (28). This system is, therefore, ideally suited to 
investigate human NK-cell differentiation in addition to being a 
reliable method to generate NK cells for therapy (29, 30).
Here, we used this ex vivo differentiation system for a complete 
transcriptomic profiling of cells in different stages of NK-cell 
development. We identified the 20 most differentially expressed 
transcription factor genes and confirmed ZNF683/HOBIT 
mRNA as the highest upregulated transcription factor mRNA. 
The analysis of different human peripheral blood cell types 
showed preferential expression of ZNF683/HOBIT mRNA 
in NK  cells. Then, we analyzed the role of ZNF683/HOBIT 
during NK-cell differentiation in more detail. In the ex vivo dif-
ferentiation system, shRNA-mediated knockdown of ZNF683/
HOBIT significantly reduced CD56−CD14− NKPs up to day 
21 of culture and nearly abrogated the following generation of 
CD56+ NK cells. The few CD56+ cells that continued to mature 
displayed normal levels of NKG2A and KIR as well as degranula-
tion capacities similar to control cells. However, the number of 
IFN-γ-producing cells significantly increased upon ZNF683/
HOBIT knockdown. Taken together, these results support that 
ZNF683/HOBIT is a key regulator of early stages of human 
NK-cell differentiation and, in later stages, may function to 
repress IFN-γ production.
MaTerials anD MeThODs
Ex Vivo Differentiation of cD34+ stem 
cells into nK cells
Human umbilical cord blood samples were obtained at birth 
after full-term delivery from the Department of Obstetrics and 
Gynecology of the University Hospital of Vienna, Austria. Cord 
blood mononuclear cells (CBMCs) were collected by Ficoll den-
sity gradient centrifugation (Lympholyte Cell Separation Media, 
human, Cedarlane®, Burlington, ON, Canada). Stem cells were 
isolated from CBMCs according to manufacturer’s protocol, using 
a magnetic bead-based CD34+ isolation kit (CD34 MicroBead Kit, 
human; Miltenyi Biotec, Bergisch Gladbach, Germany). The purity 
of the stem cells was evaluated by flow cytometry (CD34+ reached 
at least 95% purity) after which the cells were cultured as previ-
ously described (28, 30). In short, stem cells at an initial density of 
105 cells/ml were seeded into 6-well plates (Corning Incorporated, 
Corning, NY, USA) for 10  days in basal expansion medium 
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(GBGM©; Glycostem Therapeutics, Oss, The Netherlands) sup-
plemented with stem cell factor (SCF), interleukin-7 (IL-7), throm-
bopoietin (TPO), and FMS-like tyrosine kinase 3 ligand (Flt3L); 
all factors at a concentration of 25  ng/ml (CellGro®, CellGenix 
GmbH, Freiburg, Germany) and granulocyte colony-stimulating 
factor (G-CSF, 250  pg/ml; Stemcell Technologies, Vancouver, 
BC, Canada), granulocyte-macrophage colony-stimulating factor 
(GM-CSF, 10  pg/ml; Stemcell Technologies), and IL-6 (50  pg/
ml; CellGenix GmbH). At day 10, TPO was replaced with IL-15 
(20 ng/ml; CellGro®, CellGenix GmbH), and at day 14, Flt3L with 
IL-2 (1,000  U/mL; Chiron Corporation, Emeryville, CA, USA) 
by refreshing half of the medium. After a total culture period of 
35 days, a regular culture consisted of >95% CD56+CD3− NK cells 
as evaluated by flow cytometry.
Microarray
Total RNA was extracted from cells at different time points of the 
ex vivo culture and transcribed into cDNA using the GeneChip® 
Whole Transcript Sense Target Labeling Kit (Affymetrix, High 
Wycombe, UK). The labeled cDNA was hybridized to GeneChip 
Human Gene 1.0ST Arrays, and the arrays were scanned and ana-
lyzed according to protocols of the manufacturer1 as described 
in Ref. (31). Robust multiarray average signal extraction and 
normalization were performed, as detailed at the Bioconductor 
website2 (32). The microarray data have been submitted to the 
GEO database under the accession number GSE95018.
rna sampling, cDna synthesis, and 
real-time rT-Pcr
Cultured cells (5  ×  105) were lysed in Trizol (QIAzol Lysis 
Reagent, Qiagen Biosciences, MD, USA) and stored at −80°C. 
Total RNA was extracted following ThermoFishers manual3, 
and 1  µg RNA was used for cDNA synthesis according to 
manufacturer’s protocol (RevertAid H Minus First Strand cDNA 
Synthesis Kit, ThermoFisher Scientific, MA, USA). Two hundred 
nanograms of transcribed cDNA were analyzed by real-time PCR 
using the KAPA SYBR FAST UNIVERSAL kit (Kapa Biosystems, 
Inc., Wilmington, MA, USA) and primer sequences as shown in 
Table S3 in Supplementary Material. As internal controls, prim-
ers for either hypoxanthine-guanine phosphoribosyltransferase 
or β-actin were used. Samples were measured and analyzed with 
QIAGEN’s real-time PCR cycler and corresponding software 
(Rotor-Gene Q, Qiagen, Hilden, Germany).
Western Blot
For protein-expression analysis, cell pellets (5 × 105 cells/sample) 
were resuspended in 2× Laemmli buffer, boiled for 10 min at 95°C 
and subsequently separated by SDS-polyacrylamide gel electropho-
resis (10% Bis-Tris gels, Acrylamide:Bis 37.5:1) and transferred to a 
nitrocellulose membrane (Amersham Protran Supported 0.45 µm 
NC, GE Healthcare Europe GmbH, Eindhoven, The Netherlands) 
by semi-dry electrophoretic blotting in Towbin buffer with 20% 




methanol (PerfectBlue, “Semi-Dry” Electroblotter Sedec, Peqlab, 
Southampton, UK). The membrane was blocked with 5% non-fat 
dry milk in TBS-T (0.2% Tween in TBS) followed by overnight 
incubation at 4°C with primary anti-ZNF683 antibodies (goat-
anti-ZNF683 antibody C-12, 1:500, Santa Cruz Biotechnology, 
Heidelberg, Germany) or (mouse-anti-ZNF683 antibody, 1:500, 
Sigma-Aldrich, Saint Louis, MO, USA) and as control anti-GAPDH 
(mouse-anti-GAPDH, 1:10,000, Merck KGaA, Darmstadt, 
Germany). This was followed by 2 h incubation at room tempera-
ture (RT) with secondary antibodies, all 1:5,000 (donkey-anti-goat, 
Santa Cruz Biotechnology or goat-anti-mouse, Thermo Fisher 
Scientific) and corresponding washing steps with TBS-T.
lentiviral Vectors
To generate a lentiviral construct for knockdown studies, a sense 
oligo, 5′-TGGAAACACATGGGCTATGACATTTCAAGAGAA 
TGTCATAGCCCATGTGTTTCTTTTTTC-3′, corresponding 
with the sequence “GAAACACATGGGCTATGACAT” to 
position 1,402 to 1,412 from the start ATG of ZNF683/HOBIT 
cDNA (NCBI Reference Sequence: NM_001114759.2) and a cor-
responding antisense oligo, 5′-TCGAGAAAAAAGAAACACAT 
GGGCTATGACATTCTCTTGAAATGTCATAGCCCATG 
TGTTTCCA-3′ were synthesized (Integrated DNA Technologies 
Inc., Coralville, IA, USA) as complementary overlapping oligos, 
with a Xho1 overhang at the 5′end of the antisense oligo, as 
detailed.4 The complementary oligos were annealed and subse-
quently ligated into the LeGO-G/BSD lentiviral vector (LeGO-G/
BSD was a gift from Boris Fehse, Addgene plasmid #27354) that 
had been digested with HpaI and XhoI (New England Biolabs, 
Ipswich, MA, USA). The ligated product was transformed into 
the E. coli strain Stbl3 (New England Biolabs, Ipswich, MA, 
USA), recombinant colonies were selected, and plasmid-DNA 
isolated and verified by restriction digestion and Sanger sequenc-
ing. As a control, oligos containing a scrambled shRNA were 
synthesized and cloned into the LeGO-G/BSD vector using an 
identical strategy. The control shRNA sequence was obtained 
from the “Open Biosystems pGIPZ shRNAmir library” situated 
at University College London.5 To confirm the functioning of 
the shRNA, shRNA expression plasmids were co-transfected 
into HEK293 cells in the absence or presence of a commercially 
available ZNF683/HOBIT expression plasmid (ORF of ZNF683, 
transcript variant 1, in pEnter, with C-terminal Flag and His tag; 
Vigene Biosciences, Rockville, MD, USA) employing the CaPO4 
method using 4 µg of total DNA/6-well. Six hours after, transfec-
tion medium was changed, and cells were harvested 96 h after 
transfection by either direct lysis in Trizol (Qiagen) for RNA 
isolation or 1× Laemmli sample buffer for protein-expression 
analysis.
Virus Production
Virus production and all experiments involving the generated 
recombinant viruses were performed in a separate room under 
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given by the corresponding directives of the European Union 
(Council Directive 90/679/EEC) and the Austrian government 
(GTG-BGBl. Nr. 510/1994 and 114/2012). The specific work 
with the replication-defective human lentiviruses was registered 
at the Austrian Ministry of Science, Research and Economy 
(BMWFW-5.011/009-WF/V/3b/2015).
To produce lentiviruses, HEK293T cells (ATCC # CRL-11268) 
were seeded at 107 cells per 15 cm2 tissue culture plate in 15 ml 
DMEM (DMEM/high glucose, GE Healthcare) supplemented 
with 10% FBS and glutamine (200  mM, Sigma-Aldrich). After 
24  h, 5  ml DMEM was added, and the 60–70% dense cultures 
were transfected with the LeGO-G/BSD-ZNF683/HOBIT-shRNA 
expression plasmid plus three complementing plasmids provid-
ing the essential Gag, Pol, Rev, and Tat gene products missing 
in the replication-defective virus. To this end, the following 
2 transfection solutions were prepared: (1) DMEM with 10% 
polyethyleneimine (PEI, Polysciences, Warrington, PA, USA) 
(1.5 ml/15 cm2 plate) and (2) DMEM with 2.3 µg pCAG-KGP3R, 
1.2  µg pCAG-RTR2, 2.5  µg pCAG-VSVg, and 24  µg vector of 
interest (in total 30 µg plasmids in 1.55 ml/15 cm2 plate). After 
15 min incubation at RT, solution 2 was sterile filtered and added 
to solution 1. The combined solutions were added dropwise to 
HEK293T cells at a density of 70%. After 12 h, the transfection mix 
was replaced with fresh medium (12 ml DMEM/15 cm2 plate). The 
supernatants were harvested after 48 and 72 h post-transfection. 
To remove cell debris, supernatants were centrifuged (1,500 rpm, 
5 min, 4°C), filtered (Puradisc FP30mm cellulose acetate syringe 
filter, 0.45 µm, sterile, GE Healthcare Life Sciences), and finally 
the virus particles were concentrated by ultracentrifugation for 
90 min at 4°C at 25,000 rpm/76,000 × g in a SW-32 rotor equipped 
with 32  ml open-top thickwall polycarbonate tubes in a XL-70 
ultracentrifuge (Beckman Coulter, Mystic, CT, USA). After ultra-
centrifugation, the supernatant was discarded leaving a 100  µl 
drop at the bottom of the tube. The virus particles were gently 
resuspended after keeping the tubes on ice for 1 h, aliquoted, and 
stored at −80°C until use.
Virus Transduction of cD34+ stem cells
After culturing freshly isolated cord blood CD34+ stem cells 
for 5 days in basal expansion medium supplemented with SCF, 
IL-7, TPO, and Flt3L as described under “Ex vivo differentia-
tion of CD34+ stem cells into NK cells,” the expanded cells were 
transduced with lentiviral particles. To this end, 24-well plates 
(multi-well plate for suspension culture, Greiner Bio-one 
GmbH, Frickenhausen, Germany) were coated with 8  µg ret-
ronectin/500 μl/well (recombinant human fibronectin fragment, 
Takara Bio Inc., Shiga, Japan) 24 h prior virus transduction and 
stored at 4°C until use. The retronectin solution was removed, 
250  µl GBGM containing virus particles (40 Transduction 
Units/cell) were added per well, and the plate was centrifuged 
at 4,000  rpm/1,900 ×  g for 2  h at 4°C. Immediately after cen-
trifugation, the 5 days cultivated CD34+ stem cells were added 
(5 × 104 cells in 250 µl basal expansion medium/well). The fol-
lowing day, 500 µl of basal expansion medium was added. Two 
days after transduction the cells were centrifuged (1,500  rpm 
for 5  min), suspended in fresh basal medium, and transferred 
to new uncoated 24-well cell culture plates (Corning® Costar®, 
Sigma-Aldrich). Transduction efficiency, determined as GFP+ 
cells, was measured by flow cytometry 3 days after transduction, 
and cultures were continued as described in the first section (for 
ex vivo differentiation). Further cell expansion was calculated as 
follows. Cell numbers were obtained at the various differentiation 
stages and divided by the cell numbers for the corresponding 
GFP+ and GFP− fractions measured 3 days after transduction, to 
correct for different transduction efficiencies.
Flow cytometry
Cell surface expression of NK and monocytic markers was 
monitored using anti-CD56-PeCy7, anti-CD14-PerCPCy5.5 (all BD 
Biosciences, San Jose, CA, USA), and anti-KIR-PE antibodies (R&D 
Systems, Vienna, Austria) on a FACS Canto II (BD Biosciences) 
and data were analyzed using both FACS DIVA software v6.0 
(BD Biosciences) and Flowjo v10.0.8 (Tree Star, Yorba Linda, CA, 
USA). Details on antibodies are given in Table S4 in Supplementary 
Material.
cytotoxicity and iFn-γ assay
Target K562 and effector NK cells were cocultured at a 1:1 ratio 
(15 × 104 cells of each cell type) in 200 µl RPMI medium (RPMI 
1640 medium, Life Technologies, Carlsbad, CA, USA) in an 
U-bottom 96-well plate (Greiner Cellstar® 96-well plates, Sigma-
Aldrich) in the presence of anti-CD107a-APC (BD Biosciences). 
Brefeldin A and Monensin (BD Golgiplug and Golgistop, BD 
Biosciences) were added after 1 h of culture. After an additional 
5 h of culture, cells were collected, stained for surface CD56 (anti-
CD56-PeCy7, BD Biosciences), subsequently prepared for intra-
cellular staining with IFN-γ (anti-IFN-γ-PE, BD Biosciences) 
using a fixation/permeabilization solution kit (BD Biosciences), 
and finally measured on a FACS Canto II.
statistical analysis
Statistical analysis was performed with Prism 6 software 
(GraphPad, San Diego, CA, USA) using Student’s t-test or a two-
way ANOVA as indicated in Figure Legends. A p-value of 0.05 
was considered as statistically significant.
resUlTs
ZNF683/HOBIT is the Most highly 
Upregulated Transcription Factor gene 
During Ex Vivo Differentiation of human 
nK cells
Initially, we were interested to identify novel transcription fac-
tors potentially contributing to human NK-cell differentiation 
that have not been described in this function before. For this 
purpose, we employed a recently developed ex vivo differentiation 
system (29). In this system, cord blood CD34+ stem cells are ini-
tially expanded for 10 days, prior to addition of IL-15. Following 
further addition of IL-2 from day 14, the differentiating cells are 
cultured for a total period of 35–42 days, by which time a regular 
culture comprises over 95% NK cells. To determine the repertoire 
of transcription factors differentially expressed during NK-cell 




















































































FigUre 1 | high upregulation of ZnF683/hOBiT mrna during ex vivo 
differentiation of human natural killer (nK) cells correlates with 
preferential expression in peripheral blood nK cells. (a) Ten most highly 
upregulated transcription factor mRNAs during ex vivo NK cell differentiation: 
CD34+ stem cells from cord blood were expanded and ex vivo differentiated 
into NK cells. Cells were sampled at day 10, just before the differentiation into 
NK cells was initiated by the addition of IL-15, and at day 35, after 25 days of 
differentiation. RNA was isolated and subjected to real-time RT-PCR analysis. 
β-actin was used as internal control. Fold upregulation of specific mRNAs at 
day 35 compared to day 10 is shown. Results were calculated from three 
series of experiments performed in triplicates with cells from different donors 
and are displayed as mean ± SEM. (B) High expression of ZNF683/HOBIT 
mRNA in peripheral NK cells: mononuclear cells were isolated from human 
peripheral blood and one half of the cells used for isolation of NK cells by 
negative magnetic sorting. The NK cell fraction was further separated by flow 
cytometry into CD56bright and CD56dim NK cells. The second half of the 
mononuclear fraction was used to isolate CD3+ T lymphocytes, CD19+ B 
lymphocytes, and CD14+ monocytes by flow cytometry. RNA was isolated 
from the different cell samples and subjected to real-time RT-PCR analysis 
using β-actin as internal control. ZNF683/HOBIT mRNA levels within the 
different cell types are compared to the levels in the CD56bright NK cells set to 
100%. Results were obtained from three independent experiments using 
three different donors and are displayed as mean ± SEM (*p < 0.05, 
**p < 0.01, ***p < 0.001).
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comparing samples from different time points up to day 35 with 
cultures at day 10 (start of the NK-cell differentiation). The 20 
most highly upregulated transcription factor genes detected are 
shown in Table S1 in Supplementary Material. When real-time 
RT-PCR was performed for the corresponding transcripts, 
ZNF683/HOBIT mRNA was found to be by far the most highly 
upregulated mRNA at day 35 in relative terms (about 9,000-fold; 
Figure 1A). Among the most differentially expressed genes are 
many that have previously been reported to be important in 
NK-cell development and/or maturation such as GATA3 (33), 
TOX (34), ID2 (10), and ETS1 (16) (Figure  1A). Based on its 
near absence in the stem cell cultures before addition of IL-15 
and its high upregulation during differentiation, we decided to 
focus our further studies on ZNF683/HOBIT, especially as the 
role of this transcription factor in NK-cell development has not 
previously been reported.
human Peripheral Blood nK cells 
Preferentially express ZnF683/ 
hOBiT mrna
To determine if ZNF683/HOBIT is also highly expressed in adult 
peripheral blood NK cells, we performed real-time RT-PCR on 
different peripheral blood leukocyte subsets of multiple donors. 
Indeed, compared to T and B lymphocytes as well as mono-
cytes, ZNF683/HOBIT mRNA is predominantly expressed in 
NK cells (Figure 1B). CD19+ B lymphocytes display lower levels 
of ZNF683/HOBIT mRNA (about 7-fold less as compared to 
CD56dim NK cells) and the levels in T lymphocytes and monocytes 
are even much lower or at detection limit. We were furthermore 
interested to compare the ZNF683/HOBIT mRNA levels between 
the more immature CD56bright and the rather mature CD56dim 
subpopulations of NK cells. The data show that CD56bright cells 
express the highest levels of ZNF683/HOBIT mRNA, whereas 
CD56dim cells display about 20% lower levels (Figure 1B).
ZnF683/hOBiT mrna is Upregulated  
in Parallel to the generation of nK cells
To define the potential role(s) of ZNF683/HOBIT throughout 
NK-cell development, we evaluated the kinetics of accumulation 
of ZNF683/HOBIT mRNA during ex vivo differentiation. During 
this process, three different cell types can be distinguished based 
upon the monocytic and NK-cell markers, CD14 and CD56, 
respectively (28). One of the subpopulations arising from the 
amplifying CD34+ stem cells consists of monocytic CD14+ cells 
that accumulate until day 14 after which they gradually disappear 
(Figure  2A). The second population consists of CD56−CD14− 
cells, which peak at day 18. These CD56−CD14− cells are presumed 
to comprise at least in part the NK-cell progenitors as indicated 
by their rapid decrease from day 18 onward, along with the con-
comitant rapid generation of CD56+ NK cells (Figure 2A). The 
CD56+ NK cells become the predominant population after day 25 
and from day 35 onward the culture consists of over 95% CD56+ 
NK cells (Figure 2A).
We obtained samples at different time points during the 
ex vivo cultures and separated CD14− and CD14+ cells by flow 




























































FigUre 2 | Upregulation of ZnF683/hOBiT mrna during natural killer 
(nK) cell differentiation. (a) Amplification of three different cell populations 
in the ex vivo NK-cell differentiation cultures. Cord blood CD34+ cells were 
differentiated into NK cells over a culture period of 40 days. In regular 
intervals, cells were analyzed by flow cytometry for expression of the 
monocytic marker CD14 and the NK cell marker CD56. The numbers of 
CD56−CD14−, CD56+CD14−, and CD56−CD14+ cells were plotted. Results 
are calculated from 10 independent experiments using cells of different 
donors and are displayed as mean ± SEM. (B,c) Upregulation of ZNF683/
HOBIT mRNA levels. Cell samples were taken at the indicated time points 
and CD14+ cells separated from the CD14− population using magnetic 
sorting. RNA was isolated and subjected to real-time RT-PCR analysis with 
β-actin as internal control. Results are calculated from three independent 
series of experiments performed in triplicates using different donors. Fold 
upregulation in comparison to the values obtained for day 8 cells is shown as 
mean ± SEM (B). To display early ZNF683/HOBIT mRNA upregulation the 
period until day 21 is shown at a larger scale (c).
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24 onward in CD14− cells comprising NKPs and CD56+ NK cells 
(Figure  2B). The magnitude of ZNF683/HOBIT mRNA accu-
mulation actually blurs the onset of expression in the display of 
Figure 2B. When plotted at a higher magnification, it is apparent 
that ZNF683/HOBIT mRNA increased in CD14− cells already 
until day 17 followed by a first exponential accumulation up to 
day 21 (Figure  2C). Although we observed low expression of 
ZNF683/HOBIT mRNA in the CD14+ monocytes at day 17, the 
following first accumulation is absent (Figure 2C) as well as the 
exponential increase later during differentiation (Figure 2B).
ZnF683/hOBiT Downmodulation 
substantially reduces expansion  
of nK Progenitors
After observing that ZNF683/HOBIT mRNA is mainly present in 
NK cells and their progenitors, we set out to elucidate the poten-
tial role(s) of ZNF683/HOBIT during NK-cell development and 
maturation in more detail. For this purpose, we performed loss-
of-function studies using a lentiviral-based shRNA-mediated 
knockdown of ZNF683/HOBIT. The appropriate functioning 
of the shRNA was confirmed by shRNA-mediated knockdown 
of ectopically expressed ZNF683/HOBIT in HEK293T cells. As 
shown in Figure 3A, expression of ZNF683/HOBIT mRNA and 
protein was strongly reduced (>90%) upon co-expression of the 
shRNA, thus confirming the proper functioning of the shRNA 
(Figure 3A).
We then continued to investigate the effects of ZNF683/HOBIT 
knockdown on ex vivo differentiation cultures. These cultures were 
transduced with lentiviruses expressing either ZNF683/HOBIT 
shRNA (shHOBIT) or a scrambled control shRNA (shControl). 
Cultures, mock-treated for the transduction procedure but 
without addition of viruses, were performed in parallel. Based 
on initial experiments that evaluated best transduction rates 
and survival in relation to days in culture, cells were transduced 
during the stem cell expansion phase 5 days after isolation. The 
presence of a GFP cassette driven by a spleen focus-forming virus 
(SFFV)-promoter enabled us to discriminate transduced GFP+ 
cells expressing the shRNA from non-transduced GFP− cells 
within the same culture in parallel (35). Regularly, transduction 
rates between 30 and 50% were achieved. Since these varied to 
some extent, we normalized obtained expansion rates for the 
analyzed fractions to the different transduction rates measured 
3 days after transduction (8 days after isolation).
Based on the fact that the expression of the NK-cell marker 
CD56 becomes significant only from day 24 onward, we decided 
to split the analysis in two parts. In the first part, we analyzed the 
NKP stage until day 21, in the second part the generation and 
maturation of CD56+ NK cells. At day 21, we observed a fourfold 
reduced expansion of the shHOBIT GFP+ cells compared to the 
shControl GFP+ cells (Figure 3C). Exemplary dot plots of the GFP 
staining are shown in Figure 3B. The GFP− cells of the shHOBIT 
culture also seemed to be somewhat reduced in comparison to the 
scrambled control and regular mock cultures, but the difference 
did not reach statistical significance.
Since at day 21 the culture comprises mainly two different 
cell types, CD56−CD14− progenitor cells and CD14+ monocytic 
cytometry. We detected that ZNF683/HOBIT mRNA is nearly 
absent after the initial expansion phase of 10 days. A tremendous 
accumulation of ZNF683/HOBIT mRNA is observed from day 
FigUre 3 | continued  
effects of transduction with lentiviruses expressing hOBiT shrna on 
total cell expansion. (a) HOBIT shRNA strongly reduces HOBIT 
expression. Lentiviral vectors expressing HOBIT shRNA were co-transfected 
with a HOBIT expression construct into HEK293T cells. After 96 h, cells were 
either used for RNA isolation or lysed in Laemmli sample buffer. The RNA 
was used for realtime RT-PCR analysis (upper part). Results are derived from 
two experiments performed in quadruplicates and shown as mean ± SD. The 
proteins in the lysed samples were separated by SDS-PAGE, Western 
blotted, and probed with anti-HOBIT antibodies (lower part). As internal 
control hypoxanthine-guanine phosphoribosyltransferase was detected by 
respective antibodies. Two experiments with comparable results were 
performed. (B,c) HOBIT shRNA reduces expansion of cells at day 21. Cord 
blood CD34+ cells were cultured for 5 days, then cells were transduced with 
lentiviruses expressing either shHOBIT or a scrambled control shRNA 
(shControl) or were mock-treated. Transduction efficiency was measured 
3 days later by flow cytometry scoring GFP-positive cells. Cells were further 
cultured and differentiated until day 21. Then flow cytometry was performed 
to evaluate expansion of transduced GFP-expressing cells. Exemplary dot 
plots for cells transduced with lentiviruses expressing shHOBIT or shControl 
or mock-transduced controls are shown in (B). The numbers of the 
transduced GFP+ cells and the non-tranduced GFP− cells in individual 
cultures was calculated from the measured cell number and the respective 
percentages determined by flow cytometry and are shown in (c). The values 
were normalized to the number of transduced or non-tranduced cells 
measured at day 8 to establish the expansion rates. Results are calculated 
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indicate that a strong inhibitory effect on a fraction of the culture 
indirectly affects the whole culture, including the GFP− part.
The number of CD56+ NK cells was too low to be analyzed in 
detail at this time point of the culture (Figures 4A,B). Together, 
the data clearly showed that knockdown of ZNF683/HOBIT 
reduces the expansion of presumptive NKPs already at day 21 of 
the culture. This suggests a role of ZNF683/HOBIT in the early 
stages of human NK-cell development before the initiation of 
CD56 expression.
ZnF683/hOBiT Downmodulation largely 
abrogates the generation of cD56+  
nK cells
The second part of our analysis focused on the formation of CD56+ 
cells and their maturation from day 21 onward. At first sight, when 
we analyzed the percentages of CD56+ NK cells formed during 
later stages at day 35, both GFP+ populations (shHOBIT and 
shControl) seemed comparable to regular cultures (>95% CD56+ 
NK cells, Figure S1 in Supplementary Material). However, when 
the number of cells was taken into account, it became apparent that 
the generation of CD56+ NK cells from the GFP+ progenitors in 
the shHOBIT pool is substantially reduced compared to the GFP+ 
control shRNA fraction. Whereas the GFP+CD56+ NK cells in the 
control shRNA cultures showed a strong expansion between days 
21 and 35, the GFP+CD56+ NK  cells in the shHOBIT cultures 
displayed almost no increase beyond day 21 and remained low 
in number (around 20% of the shControl cultures). These cells 
did not enter the typical expansion phase between days 24 and 
35 (Figures 5A,B). In contrast, the GFP− cells in the shHOBIT 
cultures displayed an expansion phase between days 21 and 30, 
although this expansion seemed reduced in comparison to the 
cells (Figure  2A), we continued to analyze these populations 
separately. Exemplary dot plots of this analysis are displayed in 
Figure 4A. The data showed that the effect can be mainly traced 
to a fourfold reduced expansion of the CD56−CD14− progenitors 
in the shHOBIT GFP+ fraction. Although smaller inhibitory 
effects were also visible for CD14+ cells of the shHOBIT GFP+ 
pool and the GFP− cells of the shHOBIT culture, both did not 
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FigUre 4 | continued  
hOBiT shrna strongly reduces the number of cD56−cD14− 
progenitor cells at day 21. Stem cells at day 5 of culture were transduced 
and further cultured until day 21. Then CD56 and CD14 expression was 
assessed by flow cytometry within the GFP+ and GFP− parts of the culture. 
(a) Exemplary flow cytometry dot plots displaying staining for CD56 and 
CD14 at day 21. (B) The relative expansion of CD56−CD14−, CD56+, and 
CD14+ cells within the GFP+ and GFP− fractions is shown. Expansion rates 
were calculated from the measured cell numbers at day 21 and the 
percentages of the different subsets obtained by flow cytometry. Differences 
in transduction efficiency were corrected for by normalizing the obtained 
values to the number of GFP+ and GFP− cells at day 8, respectively. Results 
are calculated from four independent experiments performed in triplicates 
using different donor cells and are displayed as mean ± SEM (**p < 0.01).
FigUre 4 | continued
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shControl cultures. Again this may suggest an overall indirect 
effect of the strongly compromised GFP+ cells on the GFP− part 
of the cultures.
Taken together, our data showed that knockdown of ZNF683/
HOBIT strongly abrogates the generation of CD56+ NK cells. This 
suggests that ZNF683/HOBIT downmodulation strongly affects 
NK-cell progenitors shortly before the initiation of CD56 expres-
sion and prevents the progression toward CD56+ NK cells and/
or the further proliferation of the few detected CD56+ NK cells.
The Few Developed cD56+ nK cells 
Display normal nKg2a and Kir levels
We were further interested in the phenotype of the few detected 
CD56+ NK cells. To this end, we evaluated if these cells would 
further differentiate/mature via upregulation of NKG2A and 
KIR. The expression of these important NK-cell receptors was 
measured after 35  days of cultivation and compared between 
the GFP+ cells of the shHOBIT and the shControl cultures. We 
observed high levels of NKG2A in all of the GFP+ cells of the 
cultures independent of shHOBIT or control shRNA expression 
(Figure 6A, exemplary dot plots in Figure S2 in Supplementary 
Material). The GFP− fractions also displayed high NKG2A levels 
similar to regular control cultures. Similarly, KIR expression 
was not significantly influenced by the presence or absence of 
shHOBIT or control shRNA (Figure  6A, exemplary dot plots 
in Figure S2 in Supplementary Material) and was comparable 
to the typical levels of regular cultures. In this regard, our group 
previously showed that ex vivo generated NK cells express lower 
levels of KIR than peripheral blood-NK  cells (28). Together, 
these observations demonstrate that cells starting to express 
CD56 continue to develop normally in regard of NKG2A and 
KIR expression. Furthermore, it implies ZNF683/HOBIT does 
not influence the expression of NKG2A or KIR receptors on 
CD56+ NK cells.
Degranulation capacities remain 
Unchanged, but iFn-γ Production is 
strongly induced Upon Virus Transduction 
and Further enhanced by ZnF683/hOBiT 
Knockdown
Two main functions of NK cells are cytotoxicity, the direct kill-





















































FigUre 5 | hOBiT shrna nearly abrogates formation of cD56+ 
natural killer (nK) cells. Stem cell cultures were transduced and cultured 
until day 35. The generation of CD56+ NK cells was monitored by flow 
cytometry in samples taken at days 24, 26, 28, 31 and 35. (a) Exemplary 
flow cytometry dot plots displaying staining for CD56 within the GFP+ 
fractions at days 24 and 35. (B) The formation of CD56+ cells within the 
transduced GFP+ and non-transduced GFP− fractions is shown for shHOBIT 
and shControl cultures. Expansion rates are calculated from measured cell 
numbers at the respective days and the flow cytometry-derived percentages. 
Differences in transduction efficiency were corrected for by normalizing the 
obtained values to the number of GFP+ and GFP− cells at day 8, respectively. 
Results are calculated form four independent experiments, two of them 
















































































FigUre 6 | continued
9
Post et al. ZNF683/HOBIT and NK-Cell Development
Frontiers in Immunology | www.frontiersin.org May 2017 | Volume 8 | Article 535
whether the CD56+ NK  cells differentiating under knockdown 
conditions for ZNF683/HOBIT would functionally mature, we 
tested degranulation capacity in the CD107a assay and IFN-γ 
production. Following coculture with the target cell-line K562, we 
detected similar levels of CD107a on the cell surface of all cells 
irrespective of the culture conditions (Figure 6B, exemplary dot 
plots in Figure S2 in Supplementary Material). In the same cul-
tures, we also determined the proportion of cells with intracellular 
IFN-γ. Intriguingly, the transduction with the scrambled control 
shRNA already caused a substantial increase in IFN-γ producing 
cells (up to 50%). This was further enhanced upon expression of 
the ZNF683/HOBIT shRNA leading to 80% IFN-γ-producing cells 
(Figure 6C). In contrast, only a very small fraction of the GFP− 
cells was competent to produce IFN-γ (Figure 6C). In summary, 
transduction with shRNA lentiviruses by itself leads to a higher 
proportion of NK cells with the capacity to produce IFN-γ and 
this is further increased by knockdown of ZNF683/HOBIT. The 
ZNF683/HOBIT shRNA effect is restricted to an increase in the 
number of IFN-γ-producing cells and not reflected in the level 
of IFN-γ per cell as measured by mean flourescence intensity 
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FigUre 6 | effects of hOBiT shrna on phenotype and functions of 
natural killer (nK) cells at day 35. (a) Expression of NKG2A/CD94 and 
KIR receptors. Stem cells were transduced and cultured until day 35. Then 
expression of NKG2A and KIR was measured by flow cytometry. The 
percentages of cells within the GFP+ and GFP− fractions as well as in the 
mock-treated cultures are displayed. (B) Degranulation capacity: separate 
aliquots of the day 35 cultures were cocultured with K562 target cells and 
surface CD107a measured after 6 h by flow cytometry. Percentages of 
CD107a-positive cells within the CD56 population are displayed. (c) IFN-γ 
production: the K562 cocultures were further stained for intracellular IFN-γ. 
Representative flow cytometry dot plots obtained are shown in the upper 
part. Percentages of IFN-γ positive cells within the CD56 population are 
displayed in the lower part. All results are derived from four independent 
experiments, two of them performed in triplicates, using different donor cells 
and are shown as mean ± SEM (*p < 0.05).
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IFN-γ per cell in comparison to non-transduced cells (Figure S3 in 
Supplementary Material).
DiscUssiOn
The recent decade has witnessed an enormous increase in the 
understanding of the development of different immune-cell 
lineages including the various forms of innate and adaptive 
lymphocytes from HSCs (37). Most of this knowledge is derived 
from the murine system due to the possibility of genetic manipu-
lation of the animal models. Therefore, detailed knowledge on 
the specificities of the equivalent human differentiation and 
maturation pathways and factors are still elusive. Although many 
factors may function in identical or similar ways in murine and 
human immune-cell development, certain differences are to be 
expected based on a much more rapid evolution of the immune 
system when compared to other tissues. For example, this has 
led to the convergent evolution of distinct classes of important 
NK-cell receptors with similar function but encoded by struc-
turally different genes such as the human KIR and murine Ly49 
receptors (38, 39). It is conceivable that this is also reflected in 
the transcription factor circuitry defining human and murine 
NK cells.
Due to the recent increasing interest in NK cells as therapeutic 
agents, especially for the treatment of leukemia and potentially 
also solid cancers (40, 41), a more complete understanding of 
the control of human NK-cell differentiation and maturation is 
desirable. Here, we used a feeder cell-free ex vivo system for the 
generation of human NK cells from cord blood HSCs (29). This 
system can generate therapeutic NK cells that have been proven 
to be safe in a phase I clinical trial (42). We have, furthermore, 
demonstrated that the NK cells formed using this system display 
the typical NK cell receptors, potent ADCC and produce IFN-γ 
similar to peripheral blood NK  cells (28). So this provided an 
ideal system to study transcription factors during human NK-cell 
differentiation and maturation.
Identity of cell types and their differentiation and maturation 
is controlled in large part by the action of transcription factors. 
Normally, important core transcription factors can be identified 
by the characteristics of upregulation during differentiation and 
their high expression in a relatively high cell type-specific fashion 
(43). In this regard, our transcriptomic profiling has identified a 
large number of transcription factors strongly upregulated during 
human NK-cell differentiation. Many of these have previously 
been described in the context of murine NK-cell development. 
For example, in earlier stages of NK-cell differentiation, ID2 and 
ID3 contribute via suppression of E proteins, such as E2A, the 
B-cell promoting factor. GATA3, TOX, and IKZF3 (AIOLOS) 
have been reported to promote later maturation stages of NK-cell 
development (20, 44). From these TOX has also been described 
specifically to contribute to human NK-cell differentiation, where 
it seems to control T-BET expression (21, 22).
Upon re-evaluation of the 10 most highly upregulated 
transcription factor genes from the profiling experiment, it was 
apparent that ZNF683/HOBIT mRNA was the most strongly 
upregulated. It displayed a 10-fold higher upregulation compared 
to GATA-3, the second best factor. Further analysis of different 
immune-cell types in human peripheral blood showed prefer-
ential expression of ZNF683/HOBIT mRNA in CD56+ NK cells 
when compared to B and T  lymphocytes and monocytes. We 
detected low expression levels in B cells, but it was very low to 
undetectable in T  lymphocytes and monocytes. Furthermore, 
ZNF683 is a homolog of the PRDM1 gene encoding BLIMP-1 
(ZNF683 has, therefore, also been termed HOBIT, homolog of 
Blimp-1 in T cells) (45). In the mouse, Blimp-1 has been shown 
to be a master regulator of terminal differentiation of CD8+ 
effector T  cells and plasma cells (46) and to play a role in the 
maturation of peripheral NK  cells (18). Some upregulation 
of PRDM1 was detected in our profiling analysis (Table S1 in 
Supplementary Material), but BLIMP-1 mRNA showed a much 
less dramatic increase during human NK-cell differentiation than 
ZNF683/HOBIT mRNA (Table S2 in Supplementary Material). 
Considering its selective upregulation and expression and its 
homology with BLIMP-1, an established important differentia-
tion factor, ZNF683/HOBIT appeared to fulfill the precondition 
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for a new key transcription factor controlling the development 
of human NK cells.
We further analysed ZNF683/HOBIT expression in the 
classical defined NK subsets, CD56bright and CD56dim cells. It is 
thought that the CD56bright cells are more immature, preferen-
tially produce cytokines, and will mature further into CD56dim 
cells that display potent cytotoxic activity (1). In our analysis, 
evaluation of ZNF683/HOBIT mRNA revealed high expression 
levels in both subsets with somewhat higher levels in CD56bright 
cells. Together with the kinetic analysis of ZNF683/HOBIT 
mRNA accumulation, that displayed a parallel increase with the 
generation of CD56+ NK cells, this initially suggested a prefer-
ential activity between acquisition of CD56 and the CD56bright 
cell stage. However, a closer inspection revealed significantly 
increased ZNF683/HOBIT mRNA levels already in day 14-pro-
genitors, with an exponential upregulation from day 18 onward. 
This suggests that ZNF683/HOBIT mRNA starts to be expressed 
soon after addition of IL-15 in NKPs and continuously increases 
with highest accumulation rates in parallel to the increase in 
CD56 expression. In comparison, only minor ZNF683/HOBIT 
mRNA levels appeared to be present in the CD14+ monocytic 
subset, which develops between days 10 and 20 and disappears 
thereafter.
In line with the early expression of ZNF683/HOBIT at the 
NKP stage, shRNA-mediated downmodulation of ZNF683/
HOBIT resulted in a significantly reduced expansion of trans-
duced cells already at day 21 of the culture. The majority of 
this effect could be traced to the CD56−CD14− cells containing 
at least in part the NKPs. CD56+-expressing NK cells were not 
yet detectable at significant amounts at this time point in the 
culture. This clearly supports that a first major effect of ZNF683/
HOBIT downmodulation is a reduction of proliferation and/or 
survival of NK-cell progenitors prior to the initiation of CD56 
expression. Some reduction seemed also to occur for the CD14+ 
cells in shHOBIT transduced cultures, although this did not 
reach significance. As very low levels of ZNF683/HOBIT mRNA 
appear to be expressed in CD14+ cells, we are unable to rule out 
a potential specific negative effect also upon this subset following 
HOBIT knockdown.
The second major effect became apparent when we monitored 
the acquisition of CD56 expression. CD56 or N-CAM is generally 
accepted as a major marker for human NK cells, despite that its 
function remains elusive (47). It is present on about 95% of human 
NK cells (47), but lacks a clear homolog in murine NK cells (48). 
The kinetics of accumulation of CD56−CD14− progenitors and 
CD56+ cells in the ex vivo system are compatible with the start 
of expression of CD56 by CD56−CD14− progenitors from day 20 
onward. This is indicated by the rapid decline of CD56−CD14− 
progenitors and the concomitant appearance of the CD56+ cells. 
This generation of CD56+ cells was nearly abrogated upon down-
modulation of ZNF683/HOBIT. This supports that ZNF683/
HOBIT is essential for efficient generation of CD56 expressing 
cells and/or their further proliferation or survival.
Important receptors in human NK cells are the NKG2A and 
KIR receptors (11, 49). In the ex vivo cultures, the expression 
of NKG2A starts shortly after CD56 expression (28). NKG2A 
is further expressed on the majority of the more immature 
CD56bright cells. According to the current hypothesis, when these 
cells mature into CD56dim cells, they will reduce NKG2A and 
increase KIR expression (11). Despite the substantially reduced 
number of CD56+ cells formed in the shHOBIT cultures, it was 
astonishing that these cells appeared quite normal in respect of 
NKG2A expression compared to control cultures. The observed 
levels of NKG2A expression on about 80% of CD56+ cells were 
comparable to the levels characteristic for regular cultures (28). 
Also KIR levels established with a pan-KIR antibody were similar 
to regular cultures, in the order of 5% of CD56+ cells. As previ-
ously discussed (28), in the ex vivo cultures NKG2A levels are 
similarly high as in peripheral CD56bright cells, probably due to 
the high cytokine levels in the culture. KIR levels are intermedi-
ary between CD56bright cells and CD56dim cells. This suggests that 
ex vivo-generated NK cells, in terms of receptor expression, do 
not fully mature, whereas functionally they display full cytotoxic 
capabilities. In this regard, we observed no differences in degran-
ulation capabilities against K562 targets between the shHOBIT 
and control cultures.
In contrast, it was remarkable that virus transduction by itself 
caused an increase in the proportion of IFN-γ-producing CD56+ 
NK  cells. About 50% of day 35 cells transduced with control 
shRNA viruses produced IFN-γ upon coculture with K562 
target cells, whereas only a few percent for non-transduced cells. 
Currently, it is unclear whether this is due to a priming process 
at the time of transduction at day 5 that continues to act into 
later stages of differentiation or whether it is high expression of 
shRNAs that can activate the differentiated cells. We can only 
speculate about the underlying mechanisms for this unexpected 
finding. For example, it has been described that a uridine-rich 
part of the HIV RNA (ssRNA40) can activate NK cells via TLR7/8 
signaling (50). So, maybe the presence of high levels of shRNA 
or RNA transcribed from the viral sequences could somehow 
activate the IFN-γ machinery. Irrespective of the cause of this 
effect, the increase in IFN-γ-producing cells initiated by the virus 
itself was further enhanced by knockdown of ZNF683/HOBIT. 
This suggests that ZNF683/HOBIT negatively controls the devel-
opment of IFN-γ-producing NK cells.
We have to introduce a caveat on the interpretation of the data 
for the late stages of differentiation in the ex vivo sytem. Due to the 
low numbers of GFP+ cells obtained, that further appeared to be 
too fragile for preparative sorting, we were unable to exclude that 
the few late stage GFP+ NK cells generated are derivatives of few 
cells that failed to express the shRNA and, therefore, continued 
to differentiate. It is, however, equally conceivable that ZNF683/
HOBIT knockdown is effective on proliferation and/or survival 
only within a certain time window, when the cells normally still 
proliferate, and is less effective once the cells have passed this 
stage and do not proliferate but rather further differentiate and 
mature.
While this work was in progress, a report on ZNF683/HOBIT 
was published describing that the factor is highly expressed 
in human effector-type CD8+ T cells, but not in naive or most 
memory CD8+ T cells or CD4+ helper T cells (51, 52). High levels 
of ZNF683/HOBIT were expressed in CMV-specific, but not in 
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influenza-specific CD8+ T  cells. This may explain why in our 
experiments we did not detect significant expression levels in 
peripheral T cells as we only tested the overall population of CD3+ 
T cells comprising all CD4+ and CD8+ T cells. This report also 
showed highest expression in human NK cells and low expres-
sion in dendritic cells in accordance with our data on peripheral 
NK cells and monocytes.
Currently available evidence suggests that ZNF683/HOBIT 
may be special in terms of displaying substantial differences in 
expression pattern and possibly function in different cell types in 
mice and humans. In mice, it was reported to be predominantly 
expressed in NKT  cells, a CD4+ T  cell subset with immediate 
effector functions, and to some extent in CD8+ T cells (45, 53). 
In humans, ZNF683/HOBIT is mainly expressed in NK cells and, 
as described by others, also in effector-type CD8+ T cells (51). 
Differences also seem to occur regarding the control of IFN-γ 
production. In murine NKT  cells, ZNF683/HOBIT represses 
IFN-γ and activates granzyme B production (45). In contrast, 
in human long-lived effector T  cells, ZNF683/HOBIT was 
reported to induce IFN-γ and to have no effect on granzyme B 
production (51). Our findings in human NK cells rather support 
a suppressing effect of ZNF683/HOBIT on IFN-γ production. 
This correlates with a report on BLIMP-1 describing a similar 
suppression of IFN-γ production in human NK  cells (51). No 
effect of BLIMP-1 on cytotoxicity was observed, which is also 
in agreement with our findings on ZNF683/HOBIT. Generally, 
the homology of ZNF683/HOBIT and BLIMP-1 suggests over-
lapping and synergistic activities. Both factors display highly 
conserved zinc finger domains mediating binding to DNA target 
sequences in enhancer regions of a number of genes. The DNA 
binding sites of the factors largely overlap and both can bind 
to target sequences in several identical genes including TCF7. 
Both factors seem to mainly act as transcriptional repressors (44, 
54), although for BLIMP-1 activating properties have also been 
described (55).
Taken together, our data for the first time show a role of 
ZNF683/HOBIT during differentiation of human NK cells. They 
strongly support that ZNF683/HOBIT is a key regulatory factor 
controlling generation, proliferation, and/or survival of NK-cell 
progenitors (CD56−CD14−) and is essential for efficient genera-
tion of CD56+ cells. Once CD56 expression has been acquired 
the further maturation including NK receptor expression and 
development of degranulation capacity seems to be unaf-
fected, whereas IFN-γ production appears to be constrained by 
ZNF683/HOBIT. Although a more precise identification of the 
developmental stage(s) affected will need additional investiga-
tions, the data are compatible with the possibility that ZNF683/
HOBIT may mainly act between early factors, such as NFIL3 
(56) with proposed activities at the early committed NKP stage 
and factors described to promote rather maturation of NK cells 
at later stages such as GATA-3 (33). It further remains to be 
established how this is achieved in potential interaction with 
BLIMP-1 described so far as important mainly for late stage 
maturation.
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